12:00 AM
 | 
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasimelteon: Preliminary Phase III data

Vanda said preliminary data from the run-in portion of the double-blind, U.S. Phase III RESET trial showed that once-daily 20 mg oral tasimelteon reset the body clock and aligned 4 blind patients with non-24-hour sleep wake disorder to a constant 24-hour day. The company said the period of the body clock is measured by determining the timing of peak levels of the sulfate metabolite of melatonin...

Read the full 306 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >